Tag

Tozorakimab

All articles tagged with #tozorakimab

health1 month ago•5 min saved

AZ's tozorakimab shows broad COPD benefits ahead of FDA priority review

AZ’s IL-33 inhibitor tozorakimab delivered meaningful reductions in COPD exacerbations in two pivotal trials (Oberon and Titania), cutting moderate/severe attacks by about 29–34% in former smokers and around 30% overall in current/former smokers. Benefits extended across eosinophil subgroups and included a mucus plug score reduction, suggesting broad, differentiated efficacy. The company has secured FDA priority review, positioning tozorakimab as a potential flagship COPD biologic as it competes with other pipeline therapies.

via fiercebiotech.com|

#astrazeneca #copd #fda-priority-review

healthcare1 month ago•5 min saved

AstraZeneca's tozorakimab posts big COPD trial gains, eyeing multi-billion-dollar sales

AstraZeneca reported positive Phase 3 results for its COPD therapy tozorakimab, showing reductions in moderate and severe flare-ups across broad patient groups, including current and former smokers and across a range of eosinophil counts, with up to 43% reductions in some subsets. The IL-33–targeting antibody is under FDA priority review with potential approval in early 2027, and AZ has lifted its peak sales forecast above $5 billion as it eyes a larger COPD biologics market beyond current options like Dupixent and Nucala.

via CNBC|

#astrazeneca #biologics #copd

healthcare6 months ago•2 min saved

AZ's tozorakimab delivers COPD benefit across populations in Phase 3

AstraZeneca's anti-IL-33 antibody tozorakimab posted positive Phase 3 results in COPD (Oberon and Titania), reducing the annualized rate of moderate-to-severe exacerbations versus placebo in former smokers and showing benefit across the overall population, with a favorable safety profile. The drug’s supposed differentiation comes from complete inhibition of ST2 and RAGE/EGFR signaling, unlike rivals Roche and Sanofi/Regeneron’s IL-33 blockers that produced mixed results. AZ plans to present full data at an upcoming meeting and is pursuing two additional Phase 3 trials (Prospero, Miranda), while maintaining a target of potentially $3–5 billion in peak sales if approved.

via Fierce Biotech|

#astrazeneca #copd #healthcare